Wiggins T, Markar S R, MacKenzie H, Faiz O, Zaninotto G, Hanna G B
Department Surgery & Cancer, Imperial College London.
St Mark's Hospital and Academic Institute, Harrow, United Kingdom.
Dis Esophagus. 2018 Sep 1;31(9). doi: 10.1093/dote/doy045.
Management of achalasia is potentially complex. Previous studies have identified equivalence between pneumatic dilatation and surgical cardiomyotomy in terms of clinical outcomes. However, previous research has not investigated whether a management strategies and outcomes are different in high-volume achalasia centers. This national population-based cohort study aimed to identify the treatment modalities utilized in centers, which regularly manage achalasia and those which manage it infrequently. This study also assessed rates of re-intervention and complications to establish if a volume-outcome relationship exists for the management of achalasia in England. In this study, the Hospitals Episode Statistics database was used to identify all patients treated for achalasia in England from 2002 to 2012. Primary treatment was defined as surgical cardiomyotomy, sequential pneumatic dilatation, or botulinum toxin therapy. Primary outcome measure was reintervention. Centers were divided into regular achalasia centers (≥5.7 cases per annum) and infrequent achalasia centers (<5.7 cases per annum), and were analyzed according to tertiary cancer center status. In total, there were 7,487 patients treated for achalasia. Out of 1,947 cases (26%) were treated in regular achalasia centers, with 5,540 (74%) treated in infrequent centers. In binary logistic regression modeling regular centers treated a similar proportion of patients with primary surgical cardiomyotomy (OR: 1.11 (95% CI 0.98-1.27)) and had similar rates of re-intervention to infrequent achalasia centers (HR: 1.03 (0.94-1.12)). RA-CUSUM analysis demonstrated no relationship between total hospital volume and reintervention rates. Tertiary cancer centers treated more achalasia patients with primary surgical cardiomyotomy (OR: 1.51 (95% CI 1.31-1.73)) but there was no significant difference in reintervention rates (OR: 1.05 (95% CI 0.95-1.16)). In conclusion, this analysis failed to demonstrate a volume-outcome relationship in the management of achalasia in England. This study highlights that achalasia is treated infrequently by the majority of centers.
贲门失弛缓症的管理可能很复杂。以往的研究已经确定,在临床结果方面,气囊扩张术和手术贲门肌切开术效果相当。然而,以往的研究尚未调查在高容量贲门失弛缓症治疗中心,管理策略和结果是否有所不同。这项基于全国人群的队列研究旨在确定在经常治疗贲门失弛缓症的中心和不经常治疗该病的中心所采用的治疗方式。本研究还评估了再次干预率和并发症发生率,以确定在英国贲门失弛缓症的治疗中是否存在治疗量-结果关系。在本研究中,医院事件统计数据库用于识别2002年至2012年在英国接受贲门失弛缓症治疗的所有患者。主要治疗方法定义为手术贲门肌切开术、序贯气囊扩张术或肉毒杆菌毒素治疗。主要结局指标是再次干预。中心被分为常规贲门失弛缓症治疗中心(每年≥5.7例)和非频繁贲门失弛缓症治疗中心(每年<5.7例),并根据三级癌症中心的情况进行分析。总共有7487例患者接受了贲门失弛缓症治疗。其中1947例(26%)在常规贲门失弛缓症治疗中心接受治疗,5540例(74%)在非频繁治疗中心接受治疗。在二元逻辑回归模型中,常规中心采用原发性手术贲门肌切开术治疗的患者比例相似(比值比:1.11(95%置信区间0.98-1.27)),再次干预率与非频繁贲门失弛缓症治疗中心相似(风险比:1.03(0.94-1.12))。RA-CUSUM分析表明,医院总治疗量与再次干预率之间没有关系。三级癌症中心采用原发性手术贲门肌切开术治疗的贲门失弛缓症患者更多(比值比:1.51(95%置信区间1.31-1.73)),但再次干预率没有显著差异(比值比:1.05(95%置信区间0.95-1.16))。总之,该分析未能证明在英国贲门失弛缓症的治疗中存在治疗量-结果关系。这项研究强调,大多数中心对贲门失弛缓症的治疗并不频繁。